AI Stock Analysis - Arcutis Biotherapeutics (ARQT)
Analysis generated September 13, 2025.
Arcutis Biotherapeutics, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Their primary products address conditions such as eczema, psoriasis, and vitiligo. Arcutis has shown promise in its research and development pipeline, aiming to bring innovative solutions to market where there is significant unmet medical need.
Stock Alerts - Arcutis Biotherapeutics (ARQT)
 |
Arcutis Biotherapeutics | January 12 Price is down by -6.3% in the last 24h. |
|
Arcutis Biotherapeutics | January 9 Insider Alert: Burnett Patrick is continuing selling shares |
|
Arcutis Biotherapeutics | January 7 Insider Alert: Welgus Howard G. is selling shares |
|
Arcutis Biotherapeutics | January 3 Insider Alert: Burnett Patrick is selling shares |
Download our app to get future alerts delivered in real-time.
Alternative Data for Arcutis Biotherapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 9 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 25,000 | Sign up | Sign up | Sign up |
| Employee Rating | 76 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 7 | Sign up | Sign up | Sign up |
| Facebook Followers | 2,503 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 7 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,511 | Sign up | Sign up | Sign up |
| X Followers | 621 | Sign up | Sign up | Sign up |
| X Mentions | 5 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 48 | Sign up | Sign up | Sign up |
| Linkedin Employees | 381 | Sign up | Sign up | Sign up |
About Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
| Price | $26.78 |
| Target Price | Sign up |
| Volume | 4,010,000 |
| Market Cap | $3.46B |
| Year Range | $13.04 - $31.2 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Arcutis Biotherapeutics sees FY26 ZORYVE revenue $455M-$470MJanuary 12 - Thefly.com |
 |
Arcutis Biotherapeutics: The Earnings Inflection Has ArrivedDecember 7 - SeekingAlpha |
 |
Arcutis Biotherapeutics: Behind The Big RallyDecember 1 - SeekingAlpha |
 |
Arcutis Biotherapeutics price target raised by $5 at Mizuho, here's whyNovember 28 - Thefly.com |
 |
Arcutis Biotherapeutics announces FDA acceptance of sNDA for ZORYVENovember 17 - Thefly.com |
|
Arcutis Biotherapeutics completes enrollment in INTEGUMENT-INFANT Phase 2 studyNovember 13 - Thefly.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 99M | 8.7M | 91M | 7.4M | 11M | 0.060 |
| Q2 '25 | 82M | 7.5M | 74M | -16M | -12M | -0.130 |
| Q1 '25 | 66M | 8.8M | 57M | -25M | -19M | -0.200 |
| Q4 '24 | 71M | 6.9M | 64M | -11M | -4.5M | -0.090 |
| Q3 '24 | 45M | 5.5M | 39M | -42M | -33M | -0.330 |
Insider Transactions View All
| Burnett Patrick filed to sell 94,120 shares at $29. January 7 '26 |
| Welgus Howard G. filed to sell 69,744 shares at $29. January 6 '26 |
| Burnett Patrick filed to sell 97,766 shares at $28.8. January 2 '26 |
| Burnett Patrick filed to sell 96,610 shares at $29.4. January 2 '26 |
| Burnett Patrick filed to sell 98,307 shares at $28.9. December 17 '25 |
Similar companies
Read more about Arcutis Biotherapeutics (ARQT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Arcutis Biotherapeutics?
The Market Cap of Arcutis Biotherapeutics is $3.46B.
What is the current stock price of Arcutis Biotherapeutics?
Currently, the price of one share of Arcutis Biotherapeutics stock is $26.78.
How can I analyze the ARQT stock price chart for investment decisions?
The ARQT stock price chart above provides a comprehensive visual representation of Arcutis Biotherapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Arcutis Biotherapeutics shares. Our platform offers an up-to-date ARQT stock price chart, along with technical data analysis and alternative data insights.
Does ARQT offer dividends to its shareholders?
As of our latest update, Arcutis Biotherapeutics (ARQT) does not offer dividends to its shareholders. Investors interested in Arcutis Biotherapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Arcutis Biotherapeutics?
Some of the similar stocks of Arcutis Biotherapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.
